NCT05754411View on ClinicalTrials.gov

[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

June 22, 2023

Study Completion Date

November 9, 2023

Conditions
COVID-19
Interventions
DRUG

[14C]STI-1558

Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.

Trial Locations (1)

Unknown

Beijing Gaobo Boren Hospital, Beijing

All Listed Sponsors
lead

Zhejiang ACEA Pharmaceutical Co. Ltd.

INDUSTRY

NCT05754411 - [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects | Biotech Hunter | Biotech Hunter